[HTML][HTML] Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
For patients presenting with limited metastatic disease burden, known as the oligometastatic
state of disease, a more aggressive treatment approach targeting the new or progressive …
state of disease, a more aggressive treatment approach targeting the new or progressive …
Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status—results from a Finnish nation-wide population …
L Laru, H Ronkainen, P Ohtonen… - World Journal of Surgical …, 2021 - Springer
Background The purpose of this study was to evaluate the effects of cytoreductive
nephrectomy (CN) and metastasectomies on the survival of patients with synchronous …
nephrectomy (CN) and metastasectomies on the survival of patients with synchronous …
Transition to targeted therapies improved the prognosis and increased the utilization of medical treatments among patients with synchronous metastatic renal cell …
L Laru, H Ronkainen… - International Journal of …, 2021 - Wiley Online Library
Since the introduction of targeted therapies (TTs) for metastatic renal cell cancer (mRCC) in
2005, a limited amount of epidemiological data on efficacy of modern drug therapies for …
2005, a limited amount of epidemiological data on efficacy of modern drug therapies for …
[HTML][HTML] Сравнение прогностических факторов, влияющих на выживаемость пациентов с метахронными и синхронными метастазами почечно-клеточного …
ДВ Семенов, РВ Орлова, ВИ Широкорад… - Вестник …, 2022 - cyberleninka.ru
Введение. У пациентов с метастатическим почечноклеточным раком (мПКР) остаются
неясными различия в выживаемости без прогрессирования (ВБП) и общей …
неясными различия в выживаемости без прогрессирования (ВБП) и общей …
[HTML][HTML] A retrospective single-centered, comprehensive targeted genetic sequencing analysis of prognostic survival using tissues from Korean patients with …
Purpose To identify candidate gene mutations to significantly predict the risk of survival
prognosis after treatment with systemic first-line targeted therapy (TT) in metastatic renal cell …
prognosis after treatment with systemic first-line targeted therapy (TT) in metastatic renal cell …
[HTML][HTML] Comparison of prognostic factors that affect the survival of patients with metachronous and synchronous metastases of renal cell carcinoma
DV Semenov, RV Orlova, VI Shirokorad, SV Kostritsky… - Urology Herald, 2022 - urovest.ru
Introduction. The differences in progression-free survival (PFS) and overall survival (OS)
depending on the line of systemic therapy, the timing of the onset of metastases, and Heng …
depending on the line of systemic therapy, the timing of the onset of metastases, and Heng …
ВЕСТНИК УРОЛОГИИ
ДВ СЕМЕНОВ, РВ ОРЛОВА, ВИ ШИРОКОРАД… - ВЕСТНИК УРОЛОГИИ …, 2022 - elibrary.ru
Введение. У пациентов с метастатическим почечноклеточным раком (мПКР) остаются
неясными различия в выживаемости без прогрессирования (ВБП) и общей …
неясными различия в выживаемости без прогрессирования (ВБП) и общей …